Table 4.
Results of univariate Cox-regression analysis for PSA-progression-free survival
| Variable | Hazard ratio | 95% CI | P value |
|---|---|---|---|
| Clinical parameters at baseline | |||
| AST (U/l) | 1 | 0.993–1.007 | 0.98 |
| ALT (U/I) | 1 | 0.957–1.044 | 0.99 |
| AP (U/I) | 1.003 | 1–1.005 | 0.03* |
| LDH (U/I) | 1.001 | 1–1.002 | 0.2 |
| PSA (μg/l) | 1 | 0.998–1.001 | 0.59 |
| Baseline PET | |||
| SUVmax | 0.926 | 0.855–1.003 | 0.06 |
| PSMA-TV (cm3) | 0.99 | 0.997–1.002 | 0.66 |
| DDR-markers | |||
| Baseline | |||
| γ-H2AX foci per cell | 0.054 | 0.002–1.819 | 0.1 |
| 53BP1 foci per cell | 0.024 | 0.001–1.025 | 0.05 |
| + 1 h after administration | |||
| γ-H2AX foci per cell | 1.779 | 0.164–19.336 | 0.64 |
| 53BP1 foci per cell | 1.897 | 0.421–8.539 | 0.4 |
| + 24 h after administration | |||
| γ-H2AX foci per cell | 1.565 | 0.106–23.167 | 0.74 |
| 53BP1 foci per cell | 1.227 | 0.21–7.176 | 0.82 |
ALT, alanine transaminase; AP, alkaline phosphatase; AST, aspartate transaminase; CI, confidence interval; LDH, lactate dehydrogenase; PSA, prostate-specific antigen; PSMA, prostate-specific membrane antigen; TV, tumor volume; SUV, standardized uptake value; DDR, DNA damage response. *Reached significance